Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Amino Acid formula Clear all
Recruiting Phase 4 Interventional

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

NCT07303738
View directory record Official record
Conditions
Feeding Difficulties, Aspiration, Gastrostomy
Interventions
amino acid based formula (e.g. Elecare Jr), low bile acid binding blenderized diet (e.g. Kate Farms), high bile acid binding blenderized diet
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Nov 3, 2026, 6:17 AM EST
Completed Not applicable Interventional

Nutritional Management of Children With Chronic Diarrhea

NCT01812629
View directory record Official record
Conditions
Growth and Tolerance Infant Study
Interventions
Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 9 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Nov 3, 2026, 6:17 AM EST
Completed Not applicable Interventional

A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy

NCT00664768
View directory record Official record
Conditions
Cow Milk Allergy
Interventions
Neocate Infant, new Neocate
Dietary Supplement
Lead sponsor
Nutricia North America
Industry
Eligibility
1 Day to 8 Months
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Chandler, Arizona • Tucson, Arizona • Bentonville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Nov 3, 2026, 6:17 AM EST
Terminated Phase 1 Interventional

Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

NCT01300793
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, B-cell Lymphoma
Interventions
Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 1 Interventional

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00666692
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 1 Interventional

Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01391208
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Nov 3, 2026, 6:17 AM EST
Completed Not applicable Interventional

Infants With Protein Sensitive Colitis

NCT01813526
View directory record Official record
Conditions
Protein Sensitive Colitis
Interventions
Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 6 Months
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Nov 3, 2026, 6:17 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955
View directory record Official record
Conditions
COVID-19, Long Haul
Interventions
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
Drug · Diagnostic Test · Biological + 3 more
Lead sponsor
Well- Konnect Healthcare Services and Research Firm
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Nov 3, 2026, 6:17 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Protein Requirements for Active Children

NCT04573439
View directory record Official record
Conditions
Healthy
Interventions
Dietary Supplement: Dietary supplement: Protein intake
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 10 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 3, 2026, 6:17 AM EST
Terminated Phase 1Phase 2 Interventional Results available

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

NCT01009346
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
RAD001, Cetuximab, Cisplatin, Carboplatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional Results available

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NCT00874848
View directory record Official record
Conditions
NSCLC
Interventions
Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Nov 3, 2026, 6:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Exploratory/Proof of Principle Microbiota Study

NCT02500563
View directory record Official record
Conditions
Fecal Microbiota
Interventions
Amino acid based infant formula, Extensively hydrolyzed casein infant formula, Mother's own breast milk
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
1 Day to 7 Days
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Nov 3, 2026, 6:17 AM EST
Terminated Phase 2 Interventional

Impact of Infant Formula on Resolution of Cow's Milk Allergy

NCT02719405
View directory record Official record
Conditions
Milk Allergy
Interventions
Lactobacillus GG, Extensively Hydrolyzed Casein Formula, Amino Acid Formula
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 120 Days
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 3 Interventional

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

NCT01836575
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
Instituto Nacional de Cancer, Brazil
Government
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Leptin Treatment on Weight Loss

NCT00050791
View directory record Official record
Conditions
Obesity
Interventions
Leptin, Very Low Calorie Diet
Drug · Behavioral
Lead sponsor
Rockefeller University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

NCT01620190
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
12
States / cities
Anchorage, Alaska • Bozeman, Montana • Kennewick, Washington + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Nov 3, 2026, 6:17 AM EST
Completed No phase listed Observational

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

NCT02953223
View directory record Official record
Conditions
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome, Multiple Food Allergies
Interventions
Free amino acid infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Day to 12 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 3, 2026, 6:17 AM EST
Completed Not applicable Interventional Results available

Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis

NCT03320369
View directory record Official record
Conditions
Eosinophilic Gastroenteritis
Interventions
Elemental Diet Therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 3 Interventional Results available

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

NCT00540514
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Albumin-bound paclitaxel, Paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
31
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional Results available

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094
View directory record Official record
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00874107
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Imprime PGG® Injection, Bevacizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Fayetteville, Arkansas • Canton, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Nov 3, 2026, 6:17 AM EST
Not listed Phase 2 Interventional

The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome

NCT01966276
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
Interventions
Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos
Drug
Lead sponsor
K-PAX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Stanford, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Nov 3, 2026, 6:17 AM EST
Completed Phase 2 Interventional

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

NCT00244075
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplement, recombinant human growth hormone (rcGH), exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Nov 3, 2026, 6:17 AM EST